about
Applications of CYP450 testing in the clinical settingThe Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene.Towards the clinical implementation of pharmacogenetics in bipolar disorder.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Association of CYP2C19*2 and *3 genetic variants with essential hypertension in KoreansPharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian populationJumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.Exploring the role of drug-metabolising enzymes in antidepressant side effects.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.PharmGKB summary: citalopram pharmacokinetics pathway.Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Pharmacogenetics of chronic pain and its treatment.Abandoning personalization to get to precision in the pharmacotherapy of depression.Mechanisms of antidepressant resistanceTreatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies.Digging up the human genome: current progress in deciphering adverse drug reactions.Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.Pharmacogenomics in psychiatry - Clinical innovation utilised by the Therapeutic Goods Administration and Food and Drug Administration.Seeking an objective diagnosis of depression.A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort.A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.
P2860
Q24621760-E8749852-BFEF-4381-9E36-82B0390A3176Q26741187-45612ED8-7FEA-4CDA-A182-4E570500C7BCQ26996411-C4C9321C-FB79-4D1A-8692-EF7BD3395600Q33652540-CF72A1A9-5D4B-45C8-B049-36DBBFA12BE9Q33688133-1FF11876-6EFC-47FA-93F1-CC46E49CBFA2Q34273354-683DBCFB-6035-4FA6-AB16-6DAC1CAD00B8Q34306561-EC56175D-48F1-4F87-AF1F-926125518416Q34307589-8FECB4B0-E8CC-41A5-A010-303E3B33F9A5Q34706677-411EAB98-1A2B-4BE3-B9C6-8684C7D2EF5AQ34879739-09F702D5-8CC0-4381-8F8D-2E1DBB4561F3Q35537682-BB27090C-077F-47B2-A5A3-5C2214591A8CQ35780023-81C8B75C-AC9B-41DE-BCC3-8F9D50375EDAQ35952367-283618D7-F11A-440D-8846-3C7B1314EEB5Q35952370-1E8B4723-00B5-44B7-97E8-946B40D8D0B2Q36113601-0953344B-D619-4701-BA0A-8CC2518510BEQ36887128-13045A36-19B5-48E1-998B-C12818538BCDQ36900075-271FF863-DB5C-41D3-BC2E-995D799E6724Q37274682-A72FE378-4055-4415-BD45-3CC0DC253F1DQ37334088-738B061A-503B-4EBF-B276-6A66E2EEBA5BQ37711609-EB163EE4-5635-4C3E-95D8-931203869AE0Q37742091-9761E492-B0EF-4FDC-A25F-DC05F66CFAF8Q38154911-6769610A-0B6A-45C3-BB1D-125F40CBF216Q38154915-57A423A8-4B8D-4628-BE33-13D5E84527DDQ38239777-622BE972-1321-4248-AD1C-86695C90D326Q38357402-607B0EA0-9E06-446C-8CC3-11F8DFA73C39Q38453405-1B845033-8141-49C3-A63E-1CBFA5EEB93CQ38484370-7B5A0D4F-82C5-4896-972E-46C3C027B07CQ38509732-6369ADD8-DC5A-46B4-B8E4-A01DF4A85582Q38731079-F677DB6F-5BED-422A-962D-F5FEFE92550DQ38983579-16313DAF-2E3C-4A11-ADD7-D20312E33F14Q39441964-4A61A297-62C2-4762-96C7-B4B6016404D7Q40569531-7E9CBEE1-2D37-4047-8270-935343598922Q41005811-9E69E343-EADF-4C2A-A21F-816DD7186320Q41288507-FBF43339-3545-4FFA-A0B5-0A3319D735EBQ41889353-D889F7B3-F865-4F8C-85EE-4B40C8272D36Q45729383-592EB3D4-68E5-45E3-B0AB-F158D4633BABQ48041467-0F224608-558D-4664-B0A1-0CAE4318AD13Q48048867-AFAF84AD-CB85-49E7-AC09-1DFACF118BC9Q48170776-05212E1C-612C-4A4F-B35A-7B067E35A509Q48235443-C041CDB2-B9E6-4807-BABB-345196F780E3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
CYP2C19 variation and citalopram response.
@ast
CYP2C19 variation and citalopram response.
@en
CYP2C19 variation and citalopram response.
@nl
type
label
CYP2C19 variation and citalopram response.
@ast
CYP2C19 variation and citalopram response.
@en
CYP2C19 variation and citalopram response.
@nl
prefLabel
CYP2C19 variation and citalopram response.
@ast
CYP2C19 variation and citalopram response.
@en
CYP2C19 variation and citalopram response.
@nl
P2093
P2860
P50
P1476
CYP2C19 variation and citalopram response.
@en
P2093
David A Mrazek
Dennis J O'Kane
Joanna M Biernacka
John L Black
Karen A Snyder
Maureen S Drews
Susanna R Stevens
P2860
P356
10.1097/FPC.0B013E328340BC5A
P577
2011-01-01T00:00:00Z